PROMUS Element(TM) China Post-Approval Study
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 10 Mar 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease
- Focus Therapeutic Use
- Acronyms PEChina
- Sponsors Boston Scientific Corporation
- 07 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 02 Sep 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 11 Sep 2012 New trial record